Development of pentagamavunon-1 complexes with glycated albumin for targeted drug delivery: Synthesis, characterization, and cytotoxicity in cancer cells

Prihapsara, Fea and Meiyanto, Edy and Khadijah, Khadijah and Artanti, Anif Nur and Hermawan, Adam (2025) Development of pentagamavunon-1 complexes with glycated albumin for targeted drug delivery: Synthesis, characterization, and cytotoxicity in cancer cells. Journal of Applied Pharmaceutical Science, 15 (5). 129 - 137. ISSN 22313354

[thumbnail of 4520_pdf.pdf] Text
4520_pdf.pdf - Published Version
Restricted to Registered users only

Download (2MB) | Request a copy

Abstract

Glycoproteins have emerged as promising agents in drug delivery due to their potential for targeted delivery. This study developed and evaluated complexes of Pentagamavunon-1 (PGV-1) with glycated bovine serum albumin to enhance cytotoxic effects against cancer cells. Bovine serum albumin nanoparticles (BSA NPs) and glycated BSA nanoparticles BSA+Lactose (Lac) NPs were synthesized and complexed with PGV-1. These complexes were characterized by particle size analysis, scanning electron microscopy, transmission electron microscopy, and Fourier transform infrared spectroscopy to confirm their successful synthesis and morphological properties. Cytotoxicity was assessed in HepG2, T47D, and Vero cell lines using MTT assays, while cellular senescence was evaluated by senescence-associated β-galactosidase staining. The results indicated that PGV-1+BSA+Lac NPs significantly increased cytotoxicity in HepG2 and T47D cancer cells compared to free PGV-1, while showing lower toxicity toward non-cancerous Vero cells and demonstrating enhanced selectivity. Furthermore, senescence analysis revealed reduced β-galactosidase activity in Vero cells treated with PGV-1+BSA+Lac NPs relative to free PGV-1, supporting the targeted action of these nanoparticles. In conclusion, PGV-1+BSA+Lac NPs not only improve the delivery efficiency and selectivity of PGV-1 but also present a promising strategy for cancer-specific drug delivery. This research advances the development of glycoprotein-based delivery systems, offering a potential platform for targeted cancer therapies. © (2025), (Open Science Publishers LLP Inc.). All rights reserved.

Item Type: Article
Additional Information: Cited by: 1; All Open Access; Gold Open Access
Uncontrolled Keywords: beta galactosidase; chemical compound; cisplatin; glycosylated albumin; nanoparticle; pentagamavunon 1; unclassified drug; absorption; Article; cancer therapy; cell viability; controlled study; cytotoxicity; drug delivery system; drug synthesis; enzyme activity; Fourier transform infrared spectroscopy; Hep-G2 cell line; human; human cell; hydrogen bond; IC50; morphology; MTT assay; particle size; pH; scanning electron microscopy; T-47D cell line; transmission electron microscopy; Vero cell line
Subjects: R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Pharmacy
Depositing User: Muh Aly Mubarok
Date Deposited: 27 Oct 2026 07:13
Last Modified: 27 Oct 2026 07:13
URI: https://ir.lib.ugm.ac.id/id/eprint/30251

Actions (login required)

View Item
View Item